Literature DB >> 12852757

Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.

Brian M Fox1, Xiangshu Xiao, Smitha Antony, Glenda Kohlhagen, Yves Pommier, Bart L Staker, Lance Stewart, Mark Cushman.   

Abstract

The indenoisoquinolines are a novel class of topoisomerase I (top1) inhibitors that are cytotoxic in cancer cell cultures and are therefore under development as potential anticancer agents. As inhibitors of the DNA religation reaction occurring after DNA cleavage by the enzyme, they are classified as top1 poisons, similar to the camptothecins. Two strategies were employed in order to further develop the structure-activity relationships of the indenoisoquinolines and enhance their therapeutic potential. The first strategy involved the synthesis of indenoisoquinoline-camptothecin hybrid molecules to take advantage of a proposed structural analogy between the indenoisoquinolines and camptothecin. The desired hybrids were synthesized by reaction of halogenated phthalides with a dihydropyrroloquinoline. The second strategy involved the attachment of various alkenyl substituents to the C-11 position of the indenoisoquinolines, which were assumed to project into the DNA minor groove. The required C-11-substituted indenoisoquinolines were synthesized by McMurry reactions of 11-ketoindenoisoquinolines with aldehydes, and the geometries of the resulting alkenes were established by nuclear Overhauser effect difference NMR spectroscopy. All of the new indenoisoquinolines were examined for cytotoxicity in human cancer cell cultures as well as for activity vs top1. Although the indenoisoquinoline-camptothecin hybrid molecules proved to be less cytotoxic and displayed less activity against top1, an analogue incorporating a 3'-aminoalkenyl substituent at the C-11 position of the indenoisoquinoline system was significantly more potent than the prototype indenoisoquinoline in both assays. These results indicate that C-11 aminoalkyl substituents that are assumed to project into the minor groove enhance the cytotoxicity and top1 inhibitory activity of the parent indenoisoquinoline system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852757     DOI: 10.1021/jm0300476

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

2.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Authors:  Christophe Marchand; Smitha Antony; Kurt W Kohn; Mark Cushman; Alexandra Ioanoviciu; Bart L Staker; Alex B Burgin; Lance Stewart; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

3.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

4.  Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Authors:  Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

5.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda Hollingshead; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 6.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

7.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

8.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

9.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

10.  Total synthesis and biological evaluation of 22-hydroxyacuminatine.

Authors:  Xiangshu Xiao; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.